Canada markets closed

scPharmaceuticals Inc. (SCPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.9900+0.0800 (+2.05%)
At close: 04:00PM EDT
3.9900 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.9100
Open4.0400
Bid3.9600 x 400
Ask4.0300 x 100
Day's Range3.8600 - 4.0784
52 Week Range3.2400 - 11.7500
Volume87,970
Avg. Volume242,468
Market Cap143.857M
Beta (5Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

    BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 5:00PM ET. Mr. Tucker will also be meeting with investors

  • GlobeNewswire

    scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

    Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host investor conference call and webcast today, Tuesday, May 14, at 4:30pm ET BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to

  • GlobeNewswire

    scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

    BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, which will be held at the NASDAQ World Headquarters in New Yo